December 26, 2025 A newly released clinical review is drawing attention within medical and regulatory communities by consolidating available evidence on the side-effect profile of a widely prescribed ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
6d
Enhancing Healthcare Cybersecurity: Integrating FAIR Risk Quantification With Zero Trust Principles
The adoption of the FAIR model was pivotal in transforming our cybersecurity strategy into a measurable, business-aligned ...
Galapagos offers deep value with €3B cash, a focused M&A strategy, and new leadership. Click here to read an analysis of GLPG ...
As part of conversations between AI healthcare leaders on the podcast AI Amplified this year, a clear picture emerged of where artificial intelligence is genuinely transforming healthcare — and where ...
Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...
Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived ...
Vietnam Investment Review on MSN
Caliway submits CBL-514 for FDA Phase 2 weight management trial
Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its ...
As the diagnostic landscape evolves, several patterns are emerging across both clinical research and market innovation.
Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 ...
GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight. But they need to be taken for years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results